Hepatorenal Syndrome - Acute Management

Key Points

• HRS-AKI is a diagnosis of advanced cirrhosis after hypovolemia, infection, nephrotoxins, obstruction, and intrinsic renal disease are evaluated.
• Stop diuretics and nephrotoxins during active AKI and treat precipitating infection or bleeding.
• Terlipressin plus albumin is preferred where available for appropriate patients.
• Norepinephrine is an effective ICU alternative vasoconstrictor.
• Monitor carefully for respiratory failure and volume overload during albumin and terlipressin therapy.
• Liver transplantation is definitive treatment.
• Dialysis is used for standard kidney-failure indications, not as a replacement for transplant evaluation.

Algorithm

1. Confirm AKI in a patient with cirrhosis and ascites.
2. Search for infection, bleeding, overdiuresis, nephrotoxins, obstruction, and intrinsic renal disease.
3. Hold diuretics and nephrotoxins and correct true intravascular depletion.
4. Use albumin according to diagnostic and therapeutic guidance while monitoring volume status.
5. If HRS-AKI remains likely, start terlipressin or norepinephrine according to setting and contraindications.
6. Monitor creatinine, urine output, blood pressure, oxygenation, and signs of ischemia or overload.
7. Evaluate urgently for liver transplantation.
8. Use renal replacement therapy for conventional indications and align escalation with goals of care.

Clinical Synopsis & Reasoning

Hepatorenal syndrome-AKI occurs in advanced cirrhosis with ascites when extreme splanchnic vasodilation and neurohormonal activation reduce effective renal perfusion despite structurally intact kidneys. It is a diagnosis made after considering more common causes of AKI, including hypovolemia, sepsis-associated tubular injury, gastrointestinal bleeding, nephrotoxic medications, urinary obstruction, and intrinsic renal disease. The modern definition emphasizes dynamic creatinine change rather than waiting for creatinine to reach a high absolute threshold.

Evaluation begins with hemodynamics and precipitating events. Infection, especially SBP, gastrointestinal bleeding, overdiuresis, diarrhea from excessive lactulose, recent large-volume paracentesis without adequate albumin, and nephrotoxins can precipitate HRS physiology. Urinalysis with heavy protein, marked hematuria, cellular casts, or abnormal renal imaging argues for structural kidney disease. Urine sodium and fractional excretion indices can be low in HRS but are not specific enough to establish the diagnosis alone.

HRS-AKI is clinically important because untreated disease can progress rapidly and reflects advanced liver failure. Response to vasoconstrictor therapy is more likely when treatment begins before severe renal dysfunction is established. Liver transplantation is the definitive therapy, while vasoconstrictors and albumin serve as bridge and organ-support strategies.

Treatment Strategy & Disposition

Stop NSAIDs and other nephrotoxins, hold diuretics during active AKI, correct true hypovolemia, and treat infection or bleeding immediately. Albumin is used during diagnostic volume assessment and as part of HRS treatment, but repeated administration should be guided by volume status because pulmonary edema is possible.

Terlipressin plus albumin is the preferred pharmacologic therapy where available for appropriate patients with HRS-AKI. Monitor oxygenation closely because terlipressin can precipitate serious respiratory failure, particularly in patients with significant volume overload, hypoxemia, or advanced multi-organ failure. In ICU settings, norepinephrine infusion is an effective alternative and requires close hemodynamic monitoring. Midodrine plus octreotide is less effective and is generally used only when better-supported vasoconstrictor options are unavailable or unsuitable.

Assess for liver transplantation urgently. Renal replacement therapy can be used for standard indications such as refractory hyperkalemia, acidosis, fluid overload, or uremic complications, particularly as a bridge to transplantation or recovery from a reversible precipitant. The decision in non-transplant candidates with progressive multi-organ failure should include realistic goals-of-care discussion because dialysis alone does not correct the underlying circulatory and hepatic failure.

Epidemiology / Risk Factors

• HRS-AKI occurs in advanced decompensated cirrhosis and is often precipitated by infection or circulatory stress.
• Risk rises with refractory ascites, hyponatremia, low blood pressure, and severe portal hypertension.
• SBP is a particularly important precipitant and albumin during SBP treatment reduces HRS risk in selected patients.
• Without liver recovery or transplantation, recurrent or progressive renal dysfunction is common.

Investigations

Vasoconstrictor Options

Pharmacology

Prognosis / Complications

• Untreated HRS-AKI has a poor short-term prognosis.
• Renal response to vasoconstrictor therapy improves short-term management but does not cure the underlying liver disease.
• Earlier treatment at lower creatinine levels is generally associated with better response.
• Combined liver-kidney transplantation may be considered when renal injury is prolonged or structural kidney disease is present.

Patient Education / Counseling

• Explain that the kidneys may be structurally intact but are receiving inadequate effective blood flow because of advanced liver disease.
• Discuss that vasoconstrictors and albumin are bridge treatments while the liver disease is addressed.
• Review potential respiratory and ischemic adverse effects of vasoconstrictor therapy.
• Transplant discussion should occur early because it is the definitive treatment for eligible patients.

Notes

HRS-AKI is often overdiagnosed when a patient with cirrhosis develops any creatinine rise. Sepsis-associated ATN, diuretic-related hypovolemia, GI bleeding, and nephrotoxic injury are common and may coexist with HRS physiology.

Treatment should proceed as a bridge to a liver strategy. A falling creatinine on vasoconstrictors is useful, but it does not reverse the portal-hypertensive circulatory disorder that caused the syndrome.

References

1. AASLD: Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome Practice Guidance — Link
2. AASLD Liver Fellow Network: Ascites, SBP and HRS Guideline Review, 2026 — Link